Company / Accounts Receivable
BioRestorative Therapies, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$15.5K
FY2025
5-year range
$5.0K / $188.4K
FY2021-FY2025
Trend
-91.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 10 years, ranging from $5,000 in FY2021 to $188,400 in FY2024.
Based on SEC 10-K filings.
$15,500 in FY2025 with a 5-year CAGR of -1.8%.
Declined from $19,300 to $15,500 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -1.1%
- 5-Year CAGR
- -1.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.8%, indicating a declining trend.
- In FY2025, accounts receivable decreased 91.8% year-over-year.
- Peak accounts receivable was recorded in FY2024.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.5K | -91.8% |
| FY2024 | $188.4K | +876.2% |
| FY2023 | $19.3K | +20.6% |
| FY2022 | $16.0K | +220.0% |
| FY2021 | $5.0K | -70.6% |
| FY2020 | $17.0K | -46.9% |
| FY2019 | $32.0K | +10.3% |
| FY2018 | $29.0K | -23.7% |
| FY2017 | $38.0K | +533.3% |
| FY2016 | $6.0K | -93.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026